Diagnostics branch of APRINOIA Therapeutics developing tools for early detection and differentiation of neurodegenerative diseases. It develops the APN-1607 (florzolotau) tau PET imaging tracer and works on blood tests, brain-focused PET systems and AI image interpretation. It aims to combine these technologies in a brain-health management platform for disease staging, monitoring and personalized care. Its published pipeline lists the tracer in Phase III development for Alzheimer’s disease in China; its June 2025 release describes ongoing regulatory review in Taiwan.
Team
Hsiou-Chi LiouHead of Corporate Development and Strategy
Lili ZhangSenior Vice President, Head of Preclinical Development
